Histologic transformation in lung cancer: when one door shuts, another opens

Area of Science:

• Oncology
• Cancer Biology
• Genetics

Background:

• Histologic transformation (HT) is a significant driver of therapeutic resistance in lung cancer.
• Transformation to small-cell lung cancer (SCLC) is frequently observed in patients with EGFR-mutated lung cancer.
• Limited data exists on the prevalence, mechanisms, and optimal management of HTs.

Purpose of the Study:

• To comprehensively review the literature on histologic transformations in lung cancer.
• To discuss the mechanisms underlying HT and lineage plasticity.
• To summarize current treatment efficacy and propose future management strategies for HTs.

Main Methods:

• Literature assessment of histologic transformations in lung cancer.
• Review of studies involving EGFR-tyrosine kinase inhibitors, molecular targeted drugs, and immune checkpoint inhibitors.
• Discussion of lineage plasticity mechanisms leading to SCLC and squamous cell carcinoma.

Main Results:

• Histologic transformation is a key factor in treatment resistance for lung cancer, particularly EGFR-mutated cases transforming to SCLC.
• Mechanisms of HT and lineage plasticity are complex and varied.
• Current treatment strategies show limited efficacy, highlighting the need for novel approaches.

Conclusions:

• Histologic transformation poses a significant clinical challenge in lung cancer management.
• Further research into the mechanisms and effective treatments for HT is crucial.
• Developing improved management strategies is essential for better patient outcomes.